Mesenchymal stem cell therapy for salivary gland dysfunction and xerostomia: a systematic review of preclinical studies

David Hebbelstrup Jensen; Roberto Stefan Oliveri; Stig-Frederik Trojahn-Kølle; Anne Fischer-Nielsen; Lena Specht; Allan Bardow Jensen; Christian von Buchwald

doi:10.1016/j.oooo.2013.11.496

Mesenchymal stem cell therapy for salivary gland dysfunction and xerostomia: a systematic review of preclinical studies

David Hebbelstrup Jensen, Roberto Stefan Oliveri, Stig-Frederik Trojahn-Kølle, Anne Fischer-Nielsen, Lena Specht, Allan Bardow Jensen, Christian von Buchwald

20 Citations (Scopus)

Abstract

The most severe forms of xerostomia and salivary gland dysfunction, as well as a severely reduced quality of life, are seen in Sjögren syndrome (SS) and after radiotherapy for head and neck cancer. For both conditions, no effective regenerative therapies yet exist. Thus, the aim of this article was to assess, through systematic review, the potential benefit of mesenchymal stem cell (MSC) therapy in radiation-induced and SS-related salivary gland dysfunction and xerostomia. We searched PubMed/MEDLINE, Embase, Web of Science, the Cochrane Database of Systematic Reviews, the World Health Organization Clinical Trials Registry Platform, and Google Scholar. We identified 6 separate study comparisons eligible for inclusion. Owing to the limited number of studies, we conclude that more randomized, adequately powered clinical trials are needed to validate the potential beneficial effect of MSCs on salivary gland dysfunction and xerostomia. Nonetheless, the preliminary studies identified in the present review were encouraging for further research.

Original language	English
Journal	Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology
Volume	117
Issue number	3
Pages (from-to)	335-342
Number of pages	8
ISSN	1079-2104
DOIs	https://doi.org/10.1016/j.oooo.2013.11.496
Publication status	Published - Mar 2014

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.oooo.2013.11.496

http://www.ncbi.nlm.nih.gov/pubmed/24528792

Cite this

Jensen, D. H., Oliveri, R. S., Trojahn-Kølle, S-F., Fischer-Nielsen, A., Specht, L., Jensen, A. B., & von Buchwald, C. (2014). Mesenchymal stem cell therapy for salivary gland dysfunction and xerostomia: a systematic review of preclinical studies. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology, 117(3), 335-342. https://doi.org/10.1016/j.oooo.2013.11.496

Mesenchymal stem cell therapy for salivary gland dysfunction and xerostomia: a systematic review of preclinical studies. / Jensen, David Hebbelstrup; Oliveri, Roberto Stefan; Trojahn-Kølle, Stig-Frederik et al.

In: Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology, Vol. 117, No. 3, 03.2014, p. 335-342.

Research output: Contribution to journal › Journal article › Research › peer-review

Jensen, DH, Oliveri, RS, Trojahn-Kølle, S-F, Fischer-Nielsen, A , Specht, L, Jensen, AB & von Buchwald, C 2014, 'Mesenchymal stem cell therapy for salivary gland dysfunction and xerostomia: a systematic review of preclinical studies', Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology, vol. 117, no. 3, pp. 335-342. https://doi.org/10.1016/j.oooo.2013.11.496

@article{8545dc950f6046a2878d32f696a682d1,

title = "Mesenchymal stem cell therapy for salivary gland dysfunction and xerostomia: a systematic review of preclinical studies",

abstract = "The most severe forms of xerostomia and salivary gland dysfunction, as well as a severely reduced quality of life, are seen in Sj{\"o}gren syndrome (SS) and after radiotherapy for head and neck cancer. For both conditions, no effective regenerative therapies yet exist. Thus, the aim of this article was to assess, through systematic review, the potential benefit of mesenchymal stem cell (MSC) therapy in radiation-induced and SS-related salivary gland dysfunction and xerostomia. We searched PubMed/MEDLINE, Embase, Web of Science, the Cochrane Database of Systematic Reviews, the World Health Organization Clinical Trials Registry Platform, and Google Scholar. We identified 6 separate study comparisons eligible for inclusion. Owing to the limited number of studies, we conclude that more randomized, adequately powered clinical trials are needed to validate the potential beneficial effect of MSCs on salivary gland dysfunction and xerostomia. Nonetheless, the preliminary studies identified in the present review were encouraging for further research.",

author = "Jensen, {David Hebbelstrup} and Oliveri, {Roberto Stefan} and Stig-Frederik Trojahn-K{\o}lle and Anne Fischer-Nielsen and Lena Specht and Jensen, {Allan Bardow} and {von Buchwald}, Christian",

year = "2014",

month = mar,

doi = "10.1016/j.oooo.2013.11.496",

language = "English",

volume = "117",

pages = "335--342",

journal = "Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology",

issn = "2212-4403",

publisher = "Elsevier",

number = "3",

}

TY - JOUR

T1 - Mesenchymal stem cell therapy for salivary gland dysfunction and xerostomia: a systematic review of preclinical studies

AU - Jensen, David Hebbelstrup

AU - Oliveri, Roberto Stefan

AU - Trojahn-Kølle, Stig-Frederik

AU - Fischer-Nielsen, Anne

AU - Specht, Lena

AU - Jensen, Allan Bardow

AU - von Buchwald, Christian

PY - 2014/3

Y1 - 2014/3

N2 - The most severe forms of xerostomia and salivary gland dysfunction, as well as a severely reduced quality of life, are seen in Sjögren syndrome (SS) and after radiotherapy for head and neck cancer. For both conditions, no effective regenerative therapies yet exist. Thus, the aim of this article was to assess, through systematic review, the potential benefit of mesenchymal stem cell (MSC) therapy in radiation-induced and SS-related salivary gland dysfunction and xerostomia. We searched PubMed/MEDLINE, Embase, Web of Science, the Cochrane Database of Systematic Reviews, the World Health Organization Clinical Trials Registry Platform, and Google Scholar. We identified 6 separate study comparisons eligible for inclusion. Owing to the limited number of studies, we conclude that more randomized, adequately powered clinical trials are needed to validate the potential beneficial effect of MSCs on salivary gland dysfunction and xerostomia. Nonetheless, the preliminary studies identified in the present review were encouraging for further research.

AB - The most severe forms of xerostomia and salivary gland dysfunction, as well as a severely reduced quality of life, are seen in Sjögren syndrome (SS) and after radiotherapy for head and neck cancer. For both conditions, no effective regenerative therapies yet exist. Thus, the aim of this article was to assess, through systematic review, the potential benefit of mesenchymal stem cell (MSC) therapy in radiation-induced and SS-related salivary gland dysfunction and xerostomia. We searched PubMed/MEDLINE, Embase, Web of Science, the Cochrane Database of Systematic Reviews, the World Health Organization Clinical Trials Registry Platform, and Google Scholar. We identified 6 separate study comparisons eligible for inclusion. Owing to the limited number of studies, we conclude that more randomized, adequately powered clinical trials are needed to validate the potential beneficial effect of MSCs on salivary gland dysfunction and xerostomia. Nonetheless, the preliminary studies identified in the present review were encouraging for further research.

U2 - 10.1016/j.oooo.2013.11.496

DO - 10.1016/j.oooo.2013.11.496

M3 - Journal article

C2 - 24528792

SN - 2212-4403

VL - 117

SP - 335

EP - 342

JO - Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology

JF - Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology

IS - 3

ER -

Mesenchymal stem cell therapy for salivary gland dysfunction and xerostomia: a systematic review of preclinical studies

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this